1. Cell-type specific, inducible and acute degradation of targeted protein in mice by two degron systems.
- Author
-
Yamashita M, Ogawa C, Zhang B, Kobayashi T, Nomura A, Barker C, Zou C, Yamanaka S, Hayashi KI, Shinkai Y, Moro K, Fargarasan S, Imami K, Seita J, Shirai F, Sawasaki T, Kanemaki MT, and Taniuchi I
- Subjects
- Animals, Mice, Humans, Repressor Proteins metabolism, Repressor Proteins genetics, Female, Transcription Factors metabolism, Transcription Factors genetics, Mice, Inbred C57BL, Oryza metabolism, Oryza genetics, HEK293 Cells, Mice, Knockout, Male, Degrons, Tumor Suppressor Proteins, Proteolysis
- Abstract
Despite its broad application in in vitro studies, the application of targeted protein degradation (TPD) to animal models faces considerable challenges. Here, we develop inducible and cell-type specific TPD systems in mice using two degron systems: Oryza sativa TIR1
F74G (OsTIR1)-auxin-inducible degron 2 (AID2) and human cereblon (hCRBN)-SALL4 degron (S4D). Efficient degradation of Satb1Venus protein by these systems recapitulates phenotypes observed in the Satb1-deficient mice. These TPD are successfully applied in both the fetal and neonatal stages. The OsTIR1-AID2 system proves to be effective for membrane proteins such as PD-1, emulating the effects of the anti-PD-1 antibody. Degradation of Bcl11b reveals a role of Bcl11b which was not characterized by the Cre-loxP system. Collectively, in vivo TPD technologies developed in this study enable inducible, temporal, and cell type-specific depletion of target proteins with high efficacy in mice. These technologies have a wide range of applications in the diverse fields of biological and medical research., Competing Interests: Competing interests: I.T., M.T.K., and K.H. are co-inventors to a patent application for Rosa26OsTIR1(F74G) transgenic mouse; patent applicant: RIKEN, National Institute of Genetics, and Okayama University of Science; name of inventors: I.T., M.T.K., and K.H.; application number: 2023-036211 (Examination, Japan); specific aspect of manuscript covered in patent application; Utility of Rosa26OsTIR1(F74G) transgenic mouse. The remaining authors declare no competing interests., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF